Abstract
In recent years chimeric proteins carrying bacterial toxins as their killing moiety, have been developed to selectively recognize and kill cell populations expressing speciific receptors. The involvement of Gonadotropin releasing hormone (GnRH) has been demonstrated in several adenocarcinomas and a GnRH-bacterial toxin chimeric protein (GnRH-PE66) was thus developed and found to specifically target and kill adenocarcinoma cells both in vitro and in vivo. Because of the immunogenicity and the non-specific toxicity of the bacterial toxins, we have developed new chimeric proteins, introducing apoptosis inducing proteins of the Bcl-2 family as novel killing components. Sequences encoding the human Bik, Bak or Bax proteins were fused to the GnRH coding sequence at the DNA level and were expressed in E. coli. GnRH-Bik, GnRH-Bak and GnRH-Bax new chimeric proteins efficiently and specifically inhibited the cell growth of adenocarcinoma cell lines and eventually led to cell death. All three Bcl2-proteins-based chimeric proteins seem to induce apoptosis within the target cells, without any additional cell death stimulus. Apoptosis-inducing-proteins of the Bcl-2 family targeted by the GnRH are novel potential therapeutic reagents for adenocarcinoma treatment in humans. This novel approach could be widely applied, using any molecule that binds a specific cell type, fused to an apoptosis-inducing protein.
Similar content being viewed by others
References
Nechushtan A, Yarkoni S, Marianovsky I, Lorberboum-Galski H. Adenocarcinoma cells are targeted by the new GnRHPE66 chimeric toxin through specific gonadotropin-releasing hormone binding sites. J Biol Chem1997; 272: 11597–11603.
Ben-Yehudah A, Yarkoni S, Nechushtan A, Belostotsky R, Lorberboum-Galski H. Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice. Med Oncology1999; 16: 38–45.
King JA, Miller RP. Evolutionary aspects of gonadotropinpleasing hormone and its receptor. Cell Mol Neurol1995; 15: 5–23.
Brinkmann U, Pastan I. Immunotoxins against cancer. Biochim Biophys Acta1994; 1198: 27–45.
Aqeilan R, Yarkoni S, Lorberboum-Galski H. Interleukin 2-Bax: A novel prototype of human chimeric proteins for targeted therapy. FEBS Lett1999; 457: 271–276.
Hawkins CJ, Vaux DL. The role of the Bcl-2 family of apoptosis regulatory proteins in the immune system. Semin Immunol1997; 9: 25–33.
Wang K, Yin X-M, Chao DT, Milliman CL, Korsmeyer SJ. BID:Anovel BH3 domain-only death agonist. Genes Dev1996; 10: 2859–2869.
Inohara N, Ding L, Chen S, Nunez G. Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). TIEMBO J1997; 16: 1686–1694.
Hedge R, Srinivasula SM, Ahmad M, Fernundes-Alnemri T, Alnemri ES. Blk, BH3-containing mouse protein that interacts with Bcl-2 and Bcl-XL, is a potent death agonist. J Biol Chem1998; 273: 7783–7785.
Zha J, Harada H, Osipov K, Joekel J, Walksman G, Korsmeyer SJ. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Biol Chem1997; 272: 24101–24104.
Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes and Dev1999; 13: 1899–1911.
Sattler M, Liang H, Nettesheim D, et al. Structure of BclxL-Bak peptide complex: Recognition between regulators of apoptosis. Science1997; 275: 1129–1132.
Shimizu S, Tsujimoto T. Proapoptotic BH-3 only Bcl-2 family members induce cytochrome c release, but not mitochondrial membrane potential loss, and do not directly modulate voltagedependent anion channel activity. Proc Nat Acad Sci2000; 97: 577–582.
Daniel PT, Pun KT, Ritschel S, et al. Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistantT-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice. Blood2000; 94: 1100–1107.
Tan Y, Demeter MR, Ruan H, Comb MJ.BADser-155 phsphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem2000; 275: 25865–25869.
Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell1998; 94: 481–490.
Imaizumi K, Tsuda M, Imai Y, Wanaka A, Takagi T, Tohyama M. Molecular cloning of a novel polypeptide, DP5, induced during programmedneuronal death. J Bil Chem1997; 272: 18842–1884.
Puthalakath H, Huang DC, O'reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell1999; 3: 287–296.
Emons G, Pahwa G, Brack C, Sturm R, Oberheuser F, Knuppen R. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Clin Oncol1989; 25: 215-.
Sion-Vardi N, Kaneti J, Segal-Abramson T, Giat J, Levy J, Sharoni Y. Gonadotropin-releasing hormone specific binding sites in normal and malignant renal tissue. J Urol1992; 148: 1568–1570.
Eidne KA, Flanagan CA, Harris N, Millar RP. Gonadotropinreleasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab1987; 64: 425–432.
Lambarzi N, Halmos G, Armatis P, Schally AV. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. Int J Oncol1998; 12: 671–675.
Kottler ML, Bergametti F, Carre MC, et al. Tissue-specific pattern of variant transcripts of the human gonadotropinreleasing hormone receptor gene. Eur J Endocrinol1999; 140: 561–569.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Azar, Y., Lorberboum-Galski, H. GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis 5, 531–542 (2000). https://doi.org/10.1023/A:1009689529756
Issue Date:
DOI: https://doi.org/10.1023/A:1009689529756